Zacks Research Has Optimistic Outlook of ALNY Q1 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at Zacks Research upped their Q1 2026 EPS estimates for Alnylam Pharmaceuticals in a note issued to investors on Monday, January 27th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $0.36 per share for the quarter, up from their prior forecast of $0.34. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.24) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q2 2026 earnings at $0.14 EPS.

Other equities analysts have also issued research reports about the company. TD Cowen boosted their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Piper Sandler restated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, January 21st. Finally, Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $277.16 on Wednesday. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The firm has a market capitalization of $35.75 billion, a PE ratio of -105.79 and a beta of 0.34. The business has a 50 day simple moving average of $250.02 and a 200-day simple moving average of $260.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The company’s revenue was down 33.3% compared to the same quarter last year. During the same period last year, the firm posted $1.15 EPS.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Allworth Financial LP raised its position in shares of Alnylam Pharmaceuticals by 6.8% during the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 38 shares in the last quarter. Strategic Financial Concepts LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $41,529,000. Principal Securities Inc. lifted its position in shares of Alnylam Pharmaceuticals by 881.0% during the 4th quarter. Principal Securities Inc. now owns 1,187 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 1,066 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 87.2% in the 4th quarter. Blue Trust Inc. now owns 865 shares of the biopharmaceutical company’s stock valued at $204,000 after buying an additional 403 shares in the last quarter. Finally, AustralianSuper Pty Ltd boosted its holdings in shares of Alnylam Pharmaceuticals by 15.7% in the 4th quarter. AustralianSuper Pty Ltd now owns 4,218 shares of the biopharmaceutical company’s stock valued at $993,000 after buying an additional 573 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 73,964 shares of company stock worth $20,622,925. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.